Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daclatasvir PK Interaction Study with Darunavir/Ritonavir or Lopinavir/Ritonavir
NCT02159352Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2014
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of daclatasvir in hepatitis C (HCV) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum Observed Plasma Concentration at Day 14 and Area Under the Concentration-Time Curve in 1 Dosing Interval at Day 14. Started Jun 2014; status: completed.
02
Drugs
daclatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02159352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02159352.